Bavarian Nordic wins decade-long contract with Canada

The Danish drugmaker has expanded its monkeypox/smallpox vaccine contract with the Canadian government to last ten years, increasing its total value of up to USD 470m.

Photo: Bavarian Nordic / PR

Bavarian Nordic’s monkeypox/smallpox vaccine, regionally branded as either Imvanex, Jynneos, or Imvamune, has proven a very lucrative business for the Danish drugmaker this year.

So far, a total of seven financial upgrades have resulted from various vaccine contracts being signed around the world, and today, Tuesday, Bavarian Nordic has signed another.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs